UBE2T and cancer: ,57,58,59 Here, comprehensive analyses on KRASG12D-mutated PDAC models with UBE2T deletion, covering cancer initiation, progression, metastasis, and treatment resistance, have confirmed the oncogenic role of UBE2T.